viewImugene Ltd

Imugene CEO Leslie Chong demonstrates confidence in immuno-oncology strategy with on-market purchase

The clinical stage immuno-oncology company is developing a range of new treatments seeking to activate the immune system of cancer patients.

Imugene Ltd - Imugene CEO Leslie Chong demonstrates confidence in medical strategy with on-market purchase
Chong now holds more than 3.91 million shares in the company

Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong has demonstrated confidence in the company’s immuno-oncology strategy by purchasing shares on-market.

Chong purchased 400,000 shares at 2.2 cents per share, increasing her total number of securities held in the company to more than 3.91 million shares and 77.09 million options.

CheckVacc data published in prestigious journal

In February Imugene had preclinical data and results for its licensed oncolytic virotherapy CheckVacc published in the prestigious Journal of American College of Surgeons.

Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal and Imugene’s preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CheckVacc.

While the paper details the results seen in pancreatic cancer, CheckVacc will initially be tested in patients suffering Triple-Negative Breast Cancer (TNBC), where equally important preclinical data has been collected.

Quick facts: Imugene Ltd

Price: 0.035 AUD

Market: ASX
Market Cap: $154.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read